You are here
FDA Tentatively Approves Ribasphere Tablets for the Treatment of Chronic Hepatitis C
"Ribasphere(R) Tablets 200 mg, 400 mg, and 600 mg provide the patient and physician an opportunity to significantly reduce the number of tablets a patient has to take each day. Three Rivers believes that this has the potential to lead to better patient compliance and improved patient outcomes," said Three Rivers President and CEO Donald J. Kerrish, R.Ph.
Final approval is expected upon the expiration of the brand exclusivity in December 2005. The products will be co-marketed by Three Rivers and its marketing partner PAR Pharmaceuticals (NYSE:PRX) of Spring Valley, New York.
Source: Three Rivers Pharmaceuticals